Search
Opus Genetics Inc
IRDAdd to Watchlist
3.980USD
-0.080-1.97%
Close 11-13 16:00（ET）
331.14MMarket Cap
LossP/E TTM
About Opus Genetics Inc Company
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.
Opus Genetics Inc Profile
Ticker SymbolIRD
Company nameOpus Genetics Inc
IPO dateNov 30, 2004
CEOMagrath (George)
Number of employees18
Security typeOrdinary Share
Fiscal year-endNov 30
Address8 Davis Drive
CityDURHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code27713
Phone12486819815
Websitehttps://opusgtx.com/
Ticker SymbolIRD
IPO dateNov 30, 2004
CEOMagrath (George)
Company Executives of Opus Genetics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. George Magrath
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
1.14M
-0.84%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Chief Financial Officer
Chief Financial Officer
542.38K
-2.58%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
343.02K
+7.10%
Mr. Sean Ainsworth
Mr. Sean Ainsworth
Independent Director
Independent Director
321.69K
+7.57%
Mr. Bernhard Hoffmann
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
130.49K
+22.61%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
127.51K
+19.11%
Dr. Ashwath (Ash) Jayagopal, Ph.D.
Dr. Ashwath (Ash) Jayagopal, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
57.36K
-13.15%
Dr. Benjamin R. Yerxa, Ph.D.
Dr. Benjamin R. Yerxa, Ph.D.
President, Director
President, Director
46.32K
-71.66%
Mr. Joseph K. (Joe) Schachle
Mr. Joseph K. (Joe) Schachle
Chief Operating Officer
Chief Operating Officer
12.92K
-36.89%
Mr. Ronil Patel
Mr. Ronil Patel
Chief Business Officer
Chief Business Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. George Magrath
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
1.14M
-0.84%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Chief Financial Officer
Chief Financial Officer
542.38K
-2.58%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
343.02K
+7.10%
Mr. Sean Ainsworth
Mr. Sean Ainsworth
Independent Director
Independent Director
321.69K
+7.57%
Mr. Bernhard Hoffmann
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
130.49K
+22.61%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
127.51K
+19.11%
FAQs
Who are the top five shareholders of Opus Genetics Inc?
The top five shareholders of Opus Genetics Inc are: Dr. George Magrath
How many institutions hold shares of Opus Genetics Inc (IRD)?
As of 2026Q1, 111 institutions hold shares of Opus Genetics Inc, with a combined market value of approximately 29.67M, accounting for 41.70% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 8776669.00.